Thee presence of granulocytopenia or thrombocytopenia at the start of treatment does not contraindicate Vincristin therapy.
治疗开始时出现粒细胞减少或血小板减少,并不禁忌用长春新堿治疗。
However, the significant anticoagulant properties of heparin and its potential for bleeding complications may contraindicate its use as an anti-tumor compound.
但是肝素的抗凝血活性带来的潜在出血危险限制了其在预防肿瘤转移方面的应用。
The presence of granulocytopenia or thrombocytopenia at the start of treatment does not contraindicate vincristin therapy.
治疗开始时出现粒细胞减少或血小板减少,并不表示不适用长春花堿。
The presence of granulocytopenia or thrombocytopenia at the start of treatment does not contraindicate Vincristin therapy.